Abstract
Epstein-Barr(EB)virus-associated hemophagocytic lymphohistiocytosis(EBV-HLH)onset dangerous, rapid progress, the prognosis is poor, with high mortality without treatment.The specific pathogenesis is not entirely clear, it may be related to SH2D1A gene mutation and EBV potential membrane protein 1(LMP1)concerned.Diagnosis first need to comply with hemophagocytic lymphohistiocytosis(HLH)diagnostic criteria, and there is evidence of EB virus infection, while excluding primary HLH.The preferred treatment in combination with chemotherapy, if the poor effect of chemotherapy, viable hematopoietic stem cell transplantation and monoclonal antibody therapy. Key words: Hemophagocytic lymphohistiocytosis; Epstein-barr virus; Moleculobiological pathogenesis; Diagnosis; Treatment
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call